Aurobindo Pharma completes $300 mn deal to acquire 7 oncology products from US-based firm.
According to the definitive agreements inked between the two companies, Acrotech Biopharma LLC, a subsidiary of Aurobindo, will pay an upfront purchase price of USD 160 million in cash plus up to USD 140 million on achieving regulatory and sales-based milestones for the seven products.
The acquisition has been completed on March 1. photo: Aurobindo Pharma Youtube